Weight-Based versus Fixed Dosing of Peginterferon (40kDa) Alfa-2a

Klotz U . Pathophysiological and disease-induced changes in drug distribution volume: Pharmacokinetic implications. Clin Pharmacokinet 1976;1: 204–18.

Wurtz R Itokazu G Rodvold K . Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25: 112–8.

Rowland M Tozer T . Individualization: Age and weight. In: Rowland M Tozer T , eds. Clinical pharmacokinetics concepts and applications. 3rd ed. Philadelphia: Williams & Wilkins, 1995: 230–48.

Lauer GM Walker BD . Hepatitis C virus infection. N Engl J Med 2001;345: 41–52.

Wills RJ Dennis S Speigel HE Gibson DM Nadler PI . Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin Pharmacol Ther 1984;35: 722–7.

Xu Z-X Hoffman J Patel I Joubert P . Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-interferon) and interferon α-2a to healthy subjects (abstract). Presented at the 49th Annual Meeting of the American Association for the Study of Liver Disease, Dallas, TX, November 4–6, 1998.

Algranati NE Sy S Modi MW . Branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC) (abstract). Presented at the 50th Annual Meeting of the American Association for the Study of Liver Disease, Dallas, TX, November 5–9, 1999.

Reddy KR Wright TL Pockros PJ Shiffman M Everson G Reindollar R Efficacy and Safety of pegylated (40kDa) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001;33: 433–8.

Data on file. Peginterferon alfa-2a. Nutley, NJ: Hoffmann-La Roche, Inc., 2001.

Jen JF Glue P Ezzet F Chung C Gupta SK Jacobs S Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther 2001;69: 407–21.

Zeuzem S Feinman SV Rasenack J Heathcote EJ Lai M-Y Gane E , for the Pegasys International Study Group. Peginterferon α-2a in patients with chronic hepatitis C. N Engl J Med 2000;343: 1666–72.

Heathcote EJ Shiffman ML Cooksley GE Dusheiko GM Lee SS Balart L , for the Roche Peginterferon α-2a International Study Group. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343: 1673–80.

Zhi J Teller SB Satoh H Koss-Twardy SG Luke DR . Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2a given by subcutaneous injection in healthy male volunteers. J Clin Pharmacol 1995;35: 281–4.

Lee SS Heathcote EJ Reddy KR Zeuzem S Fried MW Wright TL Prognostic factors and early predictability of sustained viral response (SVR) in patients treated with pegylated (40kDa) interferon alfa-2a (Pegasys): A new profile (abstract). Presented at the 51st Annual Meeting of the American Association for the Study of Liver Disease, Dallas, TX, October 27–31, 2000.

Davis GL Lau JYN . Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(suppl 1):122S–7S.

Poynard T McHutchison J Goodman Z Ling MH Albrecht JK . Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31: 211–8.

Lam NP Pitrak D Speralakis R Lau AH Wiley TE Layde TJ . Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997;42: 178–85.

Monto A Alonzo J Hirsch K Watson J Bass N Wright TL . Steatosis on liver biopsy in patients with hepatitis C is associated with obesity and diabetes, but not with lifetime alcohol use (abstract). Presented at the 51st Annual Meeting of the American Association for the Study of Liver Disease, Dallas, TX, October 27–31, 2000.

Clouston AD Jonsson JR Hickman I Shorthouse C Mori T Prins J Weight reduction in patients with chronic hepatitis C improves liver histology and biochemistry (abstract). Presented at the 51st Annual Meeting of the American Association for the Study of Liver Disease, Dallas, TX, October 27–31, 2000.